Assay for the identification of IgE antibody suppressors

• US 6,270,746 B1
• Filed: 02/17/1999
• Issued: 08/07/2001
• Est. Priority Date: 02/17/1999
• Status: Expired due to Fees

• Current Assignee: David H. Katz
• Original Assignee: David H. Katz
• Inventors: Katz, David H.
• Primary Examiner(s): Saunders, David
• Assistant Examiner(s): DECLOUX, AMY M
• Application Number:
  US09/251,175
• Time in Patent Office: 902 Days
• Field of Search: 424/184.1, 424/9.2, 435/7.1, 436/513
• US Class Current: 424/9.2
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 33/6854 Immunoglobulins
• CPC Class Codes: G01N 33/9493 Immunosupressants

Abstract

The invention provides an IgE and antigen-specific screening assay for use in identifying agents which suppress the IgE mediated immune response to antigen. The assay is performed in vivo in animals which hyper respond to antigen by producing exaggerated levels of IgE. The animals are sensitized to an antigen during a specific window of sensitivity which closes a day after the animal has been treated to produce the IgE hyper responsive phenotype. The screening assay is performed in the animals by treating them with a candidate IgE suppressor agent in conjunction with further immunization made after closure of the window of sensitivity defined by the invention. Positive results (indicating that the candidate agent has IgE suppressive activity) are obtained in the assay through measurement of a decline in antigen-specific IgE in the animal following its treatment with the candidate agent. The screening assay may also be utilized to measure other components of the immune response to antigen, including IgG₁ and IgG_2a antibody production.

Claims

1. A screening method for identifying agents having IgE suppressor activity, the method comprising:

(a) determining the IgE responsiveness to antigen of an animal before and after administration to the animal of a candidate IgE suppressor, wherein the animal has been treated with an IgE enhancer prior to performance of the screening method, the steps for determining such IgE responsiveness comprising;

(i) sensitizing the animal to a sensitizing antigen within a day of treatment of the animal with the IgE enhancer;

(ii) delivering a primary immunization dose of an antigen to the animal, wherein the antigen is immunologically related to the sensitizing antigen;

(iii) measuring levels of IgE in the animal;

(iv) delivering the candidate IgE suppressor to the animal; and

,

(v) measuring levels of IgE in the animal;

then,

(b) comparing the measurements obtained in step (a)(iii) with the measurements obtained in step (a)(v), wherein a decline in any of the measured values so compared indicates that the candidate IgE suppressor suppresses the production and/or activity of IgE in the animal.

2. The method according to claim 1 wherein the IgE enhancer is sublethal, whole-body irradiation.

3. The method according to claim 2 wherein the irradiation is performed at a level between 150 and 400 rads.

4. The method according to claim 1 wherein the animal in which IgE responsiveness is determined is a rodent.

5. The method according to claim 4 wherein the rodent is a mouse of the low IgE responder phenotype.

6. The method according to claim 1 wherein the animal in which IgE responsiveness is determined is one whose IgE mediated immune system correlates to the human IgE mediated immune system to an extent sufficient that the performance of a candidate IgE suppressor in the animal can be reasonably predicted to behave similarly in humans.

7. The method according to claim 1 wherein step (a)(ii) is performed within 7 days of the performance of step (a)(i).

8. The method according to claim 7 wherein step (a)(v) is performed within 14 days of the performance of step (a)(ii).

9. The method according to claim 1 wherein steps (a)(iii) and (a)(iv) are performed on the same day as step (a)(ii).

10. The method according to claim 1 further comprising the steps (a)(iii)′

, (a)(v)′ and

(b)′

wherein the levels of at least one marker for the Th2 immunophenotype are also measured in steps (a)(iii)′ and

(a)(v)′ and

then compared in step (b)′

.

11. The method according to claim 1 further comprising the steps (a)(iii)′

, (a)(v)′ and

(b)′

wherein the levels of at least one marker for the Th1 immunophenotype are also measured in steps (a)(iii)′ and

(a)(v)′ and

then compared in step (b)′

.

12. The method according to claim 1 further comprising the steps (a)(iii)′

, (a)(v)′ and

(b)′

wherein the levels of at least one of the IgG₁ and IgG_2a subclasses are also measured in steps (a)(iii)′ and

(a)(v)′

then compared in step (b)′

.

13. The method according to claim 1 wherein the animal has been treated with an IgE enhancer during the time of day in which the animal is known or determined to have lower levels of endogenously produced corticosteroids than at other times of the day.

14. The method according to claim 1 wherein the sensitization of step (a)(i) is performed within 6 to 10 hours of treatment of the animal with the IgE enhancer.

15. The method according to claim 2 further comprising the step (a)(i)′

, wherein the effect of the irradiation on the IgE responsiveness of the animal is confirmed by;

(1) measuring levels of IgE in the animal after delivery of the primary immunization dose of antigen;

(2) treating the animal with an IgE suppressor after delivery of the primary immunization dose of antigen to the animal but before the expiration of the 24 hour period following irradiation, wherein further the ablation of any IgE measured in the animal during step (a)(i)′

(1) confirms that the desired effect of the irradiation on the animal'"'"'s IgE responsiveness has occurred.

16. The method according to claim 15 wherein the IgE suppressor is a CD23+ cell.

17. The method according to claim 15 wherein the IgE suppressor is an anti-IgE antibody.

18. The method according to claim 15 wherein the IgE suppressor is a CD23+ peptide containing an IgE binding domain.

19. The method according to claim 1 wherein the levels of IgE measured in steps (iii) and (v) are of total IgE.

20. The method according to claim 1 wherein the levels of IgE measured in steps (iii) and (v) are of antigen-specific IgE.

21. The method according to claim 1 wherein the levels of IgE measured in steps (iii) and (v) are of total IgE and of antigen-specific IgE.